Ticagrelor (Brilinta) demonstrated superiority over clopidogrel in the PLATO trial, reducing cardiovascular death and MI by 16% and cardiovascular death alone by 21% in ACS patients, at the cost of increased non-CABG-related bleeding.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.